← All trials
NCT05517655
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2022
- Primary completion
- Nov 1, 2023
- Completion date
- Nov 1, 2024
- First posted
- Aug 26, 2022
- Last posted
- Aug 26, 2022
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CincinnatiLead sponsor
- University of IowaCollaborator
- University of KansasCollaborator
- University of VirginiaCollaborator
- University of CincinnatiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.